WINTON GROUP Ltd Acquires New Position in Moderna, Inc. (NASDAQ:MRNA)

WINTON GROUP Ltd bought a new position in shares of Moderna, Inc. (NASDAQ:MRNA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 18,516 shares of the company’s stock, valued at approximately $770,000.

A number of other large investors have also recently modified their holdings of the business. Wilmington Savings Fund Society FSB lifted its position in shares of Moderna by 295.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after buying an additional 587 shares during the last quarter. Venturi Wealth Management LLC lifted its holdings in shares of Moderna by 286.2% in the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares during the last quarter. Compass Planning Associates Inc acquired a new stake in shares of Moderna in the 4th quarter valued at approximately $37,000. Larson Financial Group LLC grew its holdings in shares of Moderna by 53.5% during the 3rd quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock valued at $61,000 after purchasing an additional 317 shares during the last quarter. Finally, Crowley Wealth Management Inc. acquired a new position in Moderna during the 4th quarter worth approximately $41,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on MRNA. Morgan Stanley decreased their target price on shares of Moderna from $70.00 to $38.00 and set an “equal weight” rating on the stock in a research note on Wednesday, January 15th. Evercore ISI set a $50.00 target price on Moderna in a report on Friday, February 14th. Leerink Partners cut their price target on Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a research note on Thursday, January 16th. Barclays downgraded Moderna from an “overweight” rating to an “equal weight” rating and lowered their price objective for the company from $111.00 to $45.00 in a research note on Tuesday, February 18th. Finally, Berenberg Bank lifted their target price on shares of Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a research report on Thursday, January 16th. Four research analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Moderna has a consensus rating of “Hold” and an average price target of $59.00.

Moderna Stock Performance

Shares of MRNA opened at $31.12 on Friday. The firm has a market cap of $12.03 billion, a PE ratio of -3.35 and a beta of 1.86. Moderna, Inc. has a 52-week low of $29.25 and a 52-week high of $170.47. The business’s 50 day moving average price is $34.72 and its two-hundred day moving average price is $44.38.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.